Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATRA Atara Biotherapeutics	$11.48 -6.6%	$9.83	$5.01 ▼ $18.70	$80.62M	0.26	113,079 shs	78,074 shs
LEXX Lexaria Bioscience	$0.84 +2.1%	$0.91	$0.78 ▼ $4.38	$16.36M	0.79	140,273 shs	318,344 shs
PYXS Pyxis Oncology	$1.24 +0.8%	$1.16	$0.83 ▼ $5.39	$76.82M	1.13	541,452 shs	266,270 shs
RPTX Repare Therapeutics	$1.54 -1.9%	$1.49	$0.89 ▼ $4.07	$66.16M	0.93	311,151 shs	64,765 shs

7 Stocks to Buy And Hold Forever

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATRA Atara Biotherapeutics	0.00%	+12.24%	+22.90%	+82.62%	+75.32%
LEXX Lexaria Bioscience	0.00%	-3.02%	-13.33%	-18.05%	-74.23%
PYXS Pyxis Oncology	0.00%	+16.04%	+8.85%	0.00%	-63.39%
RPTX Repare Therapeutics	0.00%	+2.28%	+3.97%	+13.77%	-46.42%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ATRA Atara Biotherapeutics	4.6169 of 5 stars	3.4	4.0	4.7	2.9	3.3	0.6
LEXX Lexaria Bioscience	3.7814 of 5 stars	3.5	5.0	0.0	3.0	3.3	0.6
PYXS Pyxis Oncology	2.4145 of 5 stars	3.4	2.0	0.0	3.5	0.8	0.6
RPTX Repare Therapeutics	2.6302 of 5 stars	3.3	3.0	0.0	1.9	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ATRA Atara Biotherapeutics	2.80	Moderate Buy	$21.00	82.93% Upside
LEXX Lexaria Bioscience	3.00	Buy	$4.00	378.18% Upside
PYXS Pyxis Oncology	2.75	Moderate Buy	$8.67	598.92% Upside
RPTX Repare Therapeutics	2.50	Moderate Buy	$4.50	192.21% Upside

Current Analyst Ratings Breakdown

Latest LEXX, RPTX, PYXS, and ATRA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/29/2025	LEXX Lexaria Bioscience	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$5.00 ➝ $4.00
7/1/2025	LEXX Lexaria Bioscience	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$7.00 ➝ $5.00
5/19/2025	PYXS Pyxis Oncology	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00 ➝ $5.00

(Data available from 8/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ATRA Atara Biotherapeutics	$188.67M	0.43	N/A	N/A	($16.89) per share	-0.68
LEXX Lexaria Bioscience	$460K	35.57	N/A	N/A	$0.48 per share	1.74
PYXS Pyxis Oncology	$16.15M	4.76	N/A	N/A	$2.03 per share	0.61
RPTX Repare Therapeutics	$53.48M	1.24	N/A	N/A	$3.56 per share	0.43

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ATRA Atara Biotherapeutics	-$85.40M	-$0.43	N/A	N/A	N/A	3.07%	-8.34%	6.61%	N/A
LEXX Lexaria Bioscience	-$5.80M	-$0.67	N/A	N/A	N/A	-1,849.19%	-157.22%	-133.69%	N/A
PYXS Pyxis Oncology	-$77.33M	-$1.60	N/A	N/A	N/A	N/A	-63.35%	-48.97%	N/A
RPTX Repare Therapeutics	-$84.69M	-$2.58	N/A	N/A	N/A	N/A	-78.25%	-66.85%	11/6/2025 (Estimated)

Latest LEXX, RPTX, PYXS, and ATRA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	PYXS Pyxis Oncology	-$0.36	-$0.30	+$0.06	-$0.30	N/A	$2.82 million
8/11/2025	Q2 2025	ATRA Atara Biotherapeutics	-$0.32	$0.19	+$0.51	$0.19	$4.23 million	$17.58 million
8/8/2025	Q2 2025	RPTX Repare Therapeutics	-$0.56	-$0.39	+$0.17	-$0.39	$2.50 million	$0.25 million
7/14/2025	Q3 2025	LEXX Lexaria Bioscience	-$0.15	-$0.21	-$0.06	-$0.21	$0.17 million	$0.17 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ATRA Atara Biotherapeutics	N/A	N/A	N/A	N/A	N/A
LEXX Lexaria Bioscience	N/A	N/A	N/A	N/A	N/A
PYXS Pyxis Oncology	N/A	N/A	N/A	N/A	N/A
RPTX Repare Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ATRA Atara Biotherapeutics	N/A	1.70	1.70
LEXX Lexaria Bioscience	N/A	3.90	3.90
PYXS Pyxis Oncology	N/A	7.75	7.75
RPTX Repare Therapeutics	N/A	6.30	6.30

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ATRA Atara Biotherapeutics	70.90%
LEXX Lexaria Bioscience	13.06%
PYXS Pyxis Oncology	39.09%
RPTX Repare Therapeutics	85.09%

Insider Ownership

Company	Insider Ownership
ATRA Atara Biotherapeutics	4.00%
LEXX Lexaria Bioscience	26.40%
PYXS Pyxis Oncology	10.60%
RPTX Repare Therapeutics	11.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ATRA Atara Biotherapeutics	330	7.02 million	6.74 million	Optionable
LEXX Lexaria Bioscience	7	19.56 million	14.40 million	Not Optionable
PYXS Pyxis Oncology	60	61.95 million	55.38 million	Optionable
RPTX Repare Therapeutics	180	42.96 million	38.02 million	Optionable

LEXX, RPTX, PYXS, and ATRA Headlines

Recent News About These Companies

Repare Therapeutics Announces Licensing Deal and Strategic Updates

August 12, 2025 | theglobeandmail.com

Repare Therapeutics (NASDAQ:RPTX) Posts Earnings Results

August 11, 2025 | marketbeat.com

Repare Therapeutics (NASDAQ:RPTX) Upgraded by Wall Street Zen to Hold Rating

August 11, 2025 | americanbankingnews.com

Repare Therapeutics (NASDAQ:RPTX) Stock Rating Upgraded by Wall Street Zen

August 10, 2025 | marketbeat.com

Repare Therapeutics Inc. (RPTX) Reports Q2 Loss, Misses Revenue Estimates

August 8, 2025 | zacks.com

Repare (RPTX) Q2 Loss Narrows 52%

August 8, 2025 | fool.com

Repare Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results

August 8, 2025 | financialpost.comF

Repare Therapeutics (RPTX) to Release Quarterly Earnings on Tuesday

July 30, 2025 | marketbeat.com

ARK Investment Management LLC Sells 875,514 Shares of Repare Therapeutics Inc. (NASDAQ:RPTX)

July 27, 2025 | marketbeat.com

Repare Therapeutics (NASDAQ:RPTX) Trading 0.6% Higher - What's Next?

July 26, 2025 | marketbeat.com

Repare Therapeutics Jumps 15% After $10M Licensing Deal With Debiopharm

July 18, 2025 | uk.finance.yahoo.com

Repare Therapeutics Inc. (RPTX) - Yahoo Finance

July 17, 2025 | finance.yahoo.com

Repare inks licensing deal with Debiopharm for lunresertib

July 16, 2025 | thepharmaletter.comT

Repare finds suitor for paused PKMYT1 inhibitor in current partner Debiopharm

July 16, 2025 | fiercebiotech.comF

Repare Therapeutics Jumps After Hours On $267M Global Licensing Deal With Debiopharm; Retail Traders Rush In

July 16, 2025 | msn.com

Repare Therapeutics Enters Exclusive Worldwide Licensing Agreement with Debiopharm for Lunresertib

July 15, 2025 | financialpost.comF

Repare Therapeutics Enters Exclusive Worldwide Licensing Agreement with Debiopharm for Lunresertib

July 15, 2025 | financialpost.comF

Repare Therapeutics Enters Exclusive Worldwide Licensing Agreement with Debiopharm for Lunresertib

July 15, 2025 | businesswire.com

Repare Therapeutics Inc (RPTX) - Investing.com

July 3, 2025 | investing.com

Repare Therapeutics Inc (RPTX) Stock Forums - Investing.com

June 30, 2025 | investing.com

Repare Therapeutics Out-Licenses Discovery Platforms to DCx Biotherapeutics in Strategic Deal

June 25, 2025 | insidermonkey.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

LEXX, RPTX, PYXS, and ATRA Company Descriptions

Atara Biotherapeutics NASDAQ:ATRA

$11.48 -0.81 (-6.59%)

Closing price 04:00 PM Eastern

Extended Trading

$11.49 +0.01 (+0.09%)

As of 04:49 PM Eastern

Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma. Its CAR T immunotherapy pipeline products include ATA3219, currently in Phase 1 trials, as well as ATA3431, under preclinical trials for the treatment of B-cell malignancies and autoimmune diseases; and ATA188 that is in Phase 2 clinical trials to treat multiple sclerosis. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research. Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California.

Lexaria Bioscience NASDAQ:LEXX

$0.84 +0.02 (+2.01%)

As of 04:00 PM Eastern

Lexaria Bioscience Corp. operates as a biotechnology company. It develops and out-licenses its patented drug delivery technology, DehydraTECH, which combines lipophilic molecules or active pharmaceutical ingredients with specific long-chain fatty acids and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing while promoting healthier oral ingestion methods. The company's DehydraTECH is used with a range of active molecules encompassing fat-soluble vitamins, pain medications, hormones, PDE5 inhibitors, antivirals, oral nicotine and its analogs, and cannabinoids. Its DehydraTECH technology evaluates therapeutic indications, including hypertension, heart disease, and diabetes; and is suitable for a variety of product formats, such as pharmaceuticals, nutraceuticals, over the counter, and consumer packaged goods. Lexaria Bioscience Corp. was incorporated in 2004 and is headquartered in Kelowna, Canada.

Pyxis Oncology NASDAQ:PYXS

$1.24 +0.01 (+0.81%)

Closing price 04:00 PM Eastern

Extended Trading

$1.25 +0.01 (+0.40%)

As of 04:40 PM Eastern

Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors. The company is also developing PYX-107, a CD40 agonist with demonstrated anti-cancer activity in patients who previously progressed on PD-(L)1 inhibitors, which is in Phase 2 clinical trial for the treatment of solid tumors, such as soft tissue sarcomas, esophageal and gastroesophageal junction, cancers, and melanoma in combination with chemotherapy, radiation therapy, and immunotherapy. It has in-license agreement with Pfizer Inc. to develop and commercialize ADC product candidates directed to certain licensed targets, including PYX-201 and PYX-203, and products containing the ADC product candidates; and Biosion USA, Inc. for development, manufacture, and commercialization of PYX-106, an IO product candidate. Pyxis Oncology, Inc. was incorporated in 2018 and is headquartered in Boston, Massachusetts.

Repare Therapeutics NASDAQ:RPTX

$1.54 -0.03 (-1.91%)

Closing price 04:00 PM Eastern

Extended Trading

$1.54 -0.01 (-0.32%)

As of 04:04 PM Eastern

Repare Therapeutics Inc., a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair. The company's lead product candidate is Camonsertib (RP-3500), an oral small molecule inhibitor under Phase ½ development for the treatment of solid tumors with specific DNA damage repair-related genomic alterations. It is also developing Lunresertib (RP-6306), a PKMYT1 Inhibitor, which is under Phase 1 clinical trial for tumors with genetic alterations characterized by CCNE1 amplification; RP-1664, an oral PLK4 inhibitor, under Phase 1 clinical trial designed to harness the synthetic lethal relationship with TRIM37 amplification or overexpression in solid tumors; and RP-3467, a polymerase theta adenosinetriphosphatase (ATPase) inhibitor, a SL target associated with BRCA mutations and other genomic alterations. The company has license and collaboration agreement with Hoffmann-La Roche Inc. and F. Hoffmann-La Roche Ltd; Bristol-Myers Squibb Company; New York University; and Ono Pharmaceutical Co., as well as a clinical study and collaboration agreement with Debiopharm to explore the synthetic lethal combination of PKMYT1 and WEE1 inhibition in cancer. Repare Therapeutics Inc. was incorporated in 2016 and is headquartered in Montréal, Canada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time